Literature DB >> 10981097

Contemporary management of refractory hypertension.

A B Alper1, D A Calhoun.   

Abstract

Refractory or resistant hypertension is conventionally defined as systolic or diastolic blood pressure that remains uncontrolled despite sustained therapy with at least three different classes of antihypertensive agents. Refractory hypertension is estimated to affect less than 5% of the general population with hypertension; however, its prevalence increases with increasing severity of blood pressure. Patients presenting with refractory hypertension usually have progressed from mild, to moderate, to severe hypertension because of lack of or inadequate treatment. Other common contributing factors include obesity, medical nonadherence, suboptimal medical regimens, excessive dietary salt ingestion, secondary forms of hypertension, sleep apnea, and ingestion of substances that interfere with treatment. Combination therapy that includes appropriate doses of a diuretic is recommended for treatment of refractory hypertension. Use of fixed-dose combinations enhances compliance through cost savings, more convenient dosing, and reduced pill burdens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981097     DOI: 10.1007/s11906-999-0055-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  21 in total

Review 1.  How smoking affects blood pressure.

Authors:  P Omvik
Journal:  Blood Press       Date:  1996-03       Impact factor: 2.835

2.  Management of patient compliance in the treatment of hypertension. Report of the NHLBI Working Group.

Authors: 
Journal:  Hypertension       Date:  1982 May-Jun       Impact factor: 10.190

Review 3.  A review of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  G L Schwartz; S G Sheps
Journal:  Curr Opin Cardiol       Date:  1999-03       Impact factor: 2.161

4.  The prevalence of obstructive sleep apnea in hypertensives.

Authors:  C J Worsnop; M T Naughton; C E Barter; T O Morgan; A I Anderson; R J Pierce
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

5.  Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.

Authors:  G R Norton; A J Woodiwiss; C Hartford; B Trifunovic; S Middlemost; A Lee; M J Allen
Journal:  Am J Hypertens       Date:  1999-06       Impact factor: 2.689

6.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.

Authors:  A G Johnson; T V Nguyen; R O Day
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

7.  White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study.

Authors:  P Palatini; F Dorigatti; E Roman; P Giovinazzo; D Piccolo; G De Venuto; M Mattarei; E Cozzutti; S Gregori; P Mormino; A C Pessina
Journal:  J Hypertens       Date:  1998-07       Impact factor: 4.844

8.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

9.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

10.  Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel.

Authors:  R A Shimkets; D G Warnock; C M Bositis; C Nelson-Williams; J H Hansson; M Schambelan; J R Gill; S Ulick; R V Milora; J W Findling
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

View more
  2 in total

Review 1.  Factors influencing the systolic blood pressure response to drug therapy.

Authors:  Carlos Campo; Julián Segura; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jan-Feb       Impact factor: 3.738

2.  Resistant hypertension workup and approach to treatment.

Authors:  Anastasios Makris; Maria Seferou; Dimitris P Papadopoulos
Journal:  Int J Hypertens       Date:  2010-12-26       Impact factor: 2.420

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.